The introduction of oral direct coagulation factor inhibitors is dramatically changing the landscape of anticoagulation delivery in patients experiencing or at risk for a thrombotic event. These novel anticoagulants can be particularly attractive for health care providers, as they deliver therapeutic anticoagulation at a fixed dose, require no routine coagulation monitoring, and have few drug interactions and no food restrictions. Herein, we will review the role of these novel anticoagulants for acute venous thromboembolism treatment, primary and secondary venous thromboembolism prevention, and management during the periprocedural period.
|Original language||English (US)|
|Journal||Current Treatment Options in Cardiovascular Medicine|
|State||Published - Aug 2014|
- Novel anticoagulants
- Venous thromboembolism treatment (VTE)
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine